The company plans to allocate a record amount to capital expenditures to build artificial-intelligence infrastructure. The company expects bookings of between $5.55 billion to $5.65 billion for the ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

A product data company sues metalworking products manufacturer for allegedly using confidential information to "knock-off" ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Industrial toolmaker Kennametal allegedly stole former software partner MachiningCloud's trade secrets to build a competing ...

Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...